Ron Philip serves as Chief Operating Officer, working across the corporate management team to shape and implement strategic corporate priorities that drive the successful development, manufacturing and commercialization of Spark Therapeutics’ current and future gene therapies.
He is responsible for leading product strategy development and execution for Spark’s early and late-stage pipeline assets, including the governance and proactive management necessary to bring more gene therapies to patients living with genetic diseases. Ron is also responsible for the commercial organization, including commercial development, global marketing, commercial operations, diagnostics, market access and patient services functions.
Ron joined Spark in 2017 and most recently served as Chief Commercial Officer. He and his team developed Spark’s novel distribution and reimbursement model to support the launch of the first gene therapy approved for a genetic disease in the United States.
With more than 20 years of experience in the pharmaceutical industry, Ron has a proven track record of improving operating performance in multiple therapeutic categories and global markets. Prior to joining Spark, he served in several senior leadership roles at Pfizer including Regional President for Africa/Middle East, Head of Global Business Unit Strategy, Head of Business Development Search and Evaluation and Commercial Development Lead within Pfizer’s Innovative Products Business.
He previously worked at Wyeth Pharmaceuticals in U.S. commercial operations, with Deloitte Consulting in their strategy and operations practice and at Merck and Co. in the manufacturing and marketing divisions.
Ron is an alumnus of Drexel University.